Full Press Release Details
ASX Announcement (Code: ASX: PRR; NASDAQ: PBMD; ISIN:US74154B2034)
CEO ADDRESS - PRIMA BIOMED LTD 2012 ANNUAL GENERAL MEETING
I would like to say thank you to our shareholders for your continued support of Prima. I am happy to have the opportunity to speak to you today about Prima s operational progress and strategic plans.
As the Chairman stated, Prima is one of the world leaders in personalized cell products. We have invested in a global production and
distribution platform to support the CVac program. I would like to show a short video that helps visualize our accomplishments.
you not in attendance today, this video will be available later today through our website at www.primabiomed.com.au.
over the coming years, we see a major opportunity for Prima to capitalize on our manufacturing expertise and technology platform. Immunotherapy for cancer is a field in its early days. We are well positioned operationally to consolidate our
leadership position in the field.
As previously advised, on the back of our recent positive immune monitoring data, we plan to initiate
exploratory trials of CVac in other cancer types that overexpress mucin 1. Pending appropriate funding, we plan to commence those programs in about the second calendar quarter of 2013. We have done significant feasibility work and will concentrate
on indications of high unmet medical need and a favorable competitive environment, as we have done with our ovarian cancer program.
term, we are actively looking at business development opportunities, both to bring in new and complementary technologies to develop additional products, and to develop the relationships for potential industry partners to market and sell the product
we develop. We have had a number of conversations in recent months with big pharma and biotech companies. The feedback is consistent and clear. Of course, everyone is interested in the efficacy of a product, which we will establish during clinical
trials, and everyone is very encouraged by the safety profile and the interim immune monitoring data with CVac. But the potential to successfully partner this product depends also on our ability to bring a robust and cost effective manufacturing
Specifically, there are three key elements to manufacturing personalized immunotherapy products:
As demonstrated in the video we have made enormous strides in all three of these areas and we will have the opportunity
through the CANVAS program to validate and test our platform. In particular, we will look at manufacturing of the first 150 patients from the CANVAS trial as a critical point for assessing our manufacturing specifications with regulators.
BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
As we continue to make progress in this immunotherapy space, I look forward to keeping everyone abreast of
Thank you, again, for your loyal support for our groundbreaking work. I am confident that our research will yield significant benefits to our investors, to the scientific community, and, most importantly,
to all the patients who need better and safer treatments for cancer.
CEO and Managing Director
BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284